Centessa Pharmaceuticals appoints new Chief Medical Officer By Investing.com

BOSTON – Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a market capitalization of $2.28 billion, announced the appointment of Stephen Kanes MD PhD as its new Chief Medical (TASE:) Officer. Dr. Kanes, a neuropsychiatrist with over 30 years of experience in neuroscience, clinical psychiatry, and drug development, joins Centessa as it advances its portfolio of orexin receptor 2 (OX2R) agonists, with multiple clinical milestones expected this year. According to InvestingPro data, the company maintains a strong financial position with liquid assets exceeding short-term obligations by a significant margin, as reflected in its impressive current ratio of 21.52.

Dr. Kanes’ expertise is anticipated to be a significant asset for Centessa, particularly as it progresses the development of novel OX2R agonists for various disorders including sleep-wake, neurological, neurodegenerative, and psychiatric conditions. The company’s CEO, Saurabh Saha MD PhD, emphasized Dr. Kanes’ exceptional skills in clinical program design and execution across key therapeutic areas. The market has shown strong confidence in Centessa’s direction, with the stock delivering an impressive 144% return over the past year. InvestingPro analysis reveals multiple positive indicators, with 4 analysts recently revising their earnings expectations upward.

The new CMO has a notable background, having served as CMO of Sage Therapeutics, where he led the development of ZULRESSO®, the first approved treatment for Postpartum Depression (PPD (NASDAQ:)). His experience also includes his role as CEO of EmbarkNeuro and earlier positions at AstraZeneca (NASDAQ:) and the University of Pennsylvania Department of Psychiatry. Dr. Kanes has contributed to over 60 peer-reviewed publications and holds a BA, PhD in Molecular and Cellular Pharmacology, and MD from the University of Pennsylvania and Stony Brook University Renaissance School of Medicine, respectively.

Centessa is focused on developing potential best-in-class oral OX2R agonists for the treatment of sleep-wake disorders and other symptoms related to neurological and psychiatric conditions. Its lead OX2R agonist, ORX750, is currently in Phase 2 clinical trials.

The company also highlighted its proprietary LockBody technology platform, aimed at redefining immuno-oncology treatments for cancer patients. LockBody drug candidates are designed to deliver potent effector function activity to the tumor micro-environment while minimizing systemic toxicity.

The announcement is based on a press release statement and contains forward-looking statements regarding the company’s research and development efforts. These statements are not guarantees of future performance and are subject to risks and uncertainties. The efficacy of ORX750 and other OX2R agonists, as well as the LockBody technology platform, have not been established, as they are in the clinical trial phase and have not received FDA approval.

In other recent news, Centessa Pharmaceuticals has been the subject of multiple positive developments. Cowen research firm initiated coverage of Centessa, assigning a Buy rating due to the potential of the company’s drug candidate ORX750, aimed at treating a range of hypersomnia indications. The firm expressed optimism about the drug’s prospects, citing its “best in class profile.”

Leerink Partners also showed confidence in Centessa, raising the stock’s price target while maintaining an Outperform rating. This follows Centessa’s announcement of a promising update to its Phase 1 ORX750 program and an increase in the company’s total sales projections for 2032 by 4%.

Guggenheim maintained a positive outlook on shares of Centessa, raising the price target and keeping a Buy rating on the stock. The firm highlighted recent strategic developments, particularly updates for ORX750, and noted these developments could significantly narrow the competitive gap in the treatment of narcolepsy.

Morgan Stanley (NYSE:) upgraded Centessa to Overweight, following the promising interim Phase 1 results of the company’s ORX750 study. These developments highlight Centessa’s ongoing efforts in the pharmaceutical industry and its potential for future success.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.